A Phase I/II Trial of BAY 43-9006 in Combination With Bevacizumab in Patients With Advanced Renal Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 21 Jan 2015
At a glance
- Drugs Bevacizumab (Primary) ; Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Jan 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 16 Jul 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.